Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful…
Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has…
Latent Labs Secures $50 Million to Pioneer AI-Driven Programmable Biology Latent Labs, an emerging leader in AI-powered biological programming, has officially stepped out of stealth mode, announcing a significant $50…
Opna Bio Secures Orphan Drug Designation for OPN-6602 in Multiple Myeloma Opna Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics, has announced that…
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has…
Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma Tivic Health Systems, Inc. (Nasdaq: TIVC) has taken a major step toward expanding its therapeutic portfolio by…
Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium Ferring Pharmaceuticals recently announced that three abstracts showcasing ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025…
Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in…
Taiho Oncology Europe Announces Availability of Futibatinib in Italy for the Treatment of Cholangiocarcinoma Taiho Oncology Europe, a subsidiary of Taiho Pharmaceutical Co., Ltd., has officially announced the availability of…
GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing…